Metabolite profiling reveals a connection between aldehyde dehydrogenase 1A3 and GABA metabolism in breast cancer metastasis
-
Published:2022-01
Issue:1
Volume:18
Page:
-
ISSN:1573-3882
-
Container-title:Metabolomics
-
language:en
-
Short-container-title:Metabolomics
Author:
Dahn Margaret L., Walsh Hayley R., Dean Cheryl A., Giacomantonio Michael A., Fernando Wasundara, Murphy J Patrick, Walker Olivia L., Wasson Marie-Claire D., Gujar Shashi, Pinto Devanand M., Marcato PaolaORCID
Abstract
Abstract
Introduction
Aldehyde dehydrogenase 1A3 (ALDH1A3) is a cancer stem cell (CSC) marker and in breast cancer it is associated with triple-negative/basal-like subtypes and aggressive disease. Studies on the mechanisms of ALDH1A3 in cancer have primarily focused on gene expression changes induced by the enzyme; however, its effects on metabolism have thus far been unstudied and may reveal novel mechanisms of pathogenesis.
Objective
Determine how ALDH1A3 alters the metabolite profile in breast cancer cells and assess potential impacts.
Method
Triple-negative MDA-MB-231 tumors and cells with manipulated ALDH1A3 levels were assessed by HPLC–MS metabolomics and metabolite data was integrated with transcriptome data. Mice harboring MDA-MB-231 tumors with or without altered ALDH1A3 expression were treated with γ-aminobutyric acid (GABA) or placebo. Effects on tumor growth, and lungs and brain metastasis were quantified by staining of fixed thin sections and quantitative PCR. Breast cancer patient datasets from TCGA, METABRIC and GEO were used to assess the co-expression of GABA pathway genes with ALDH1A3.
Results
Integrated metabolomic and transcriptome data identified GABA metabolism as a primary dysregulated pathway in ALDH1A3 expressing breast tumors. Both ALDH1A3 and GABA treatment enhanced metastasis. Patient dataset analyses revealed expression association between ALDH1A3 and GABA pathway genes and corresponding increased risk of metastasis.
Conclusion
This study revealed a novel pathway affected by ALDH1A3, GABA metabolism. Like ALDH1A3 expression, GABA treatment promotes metastasis. Given the clinical use of GABA mimics to relieve chemotherapy-induced peripheral nerve pain, further study of the effects of GABA in breast cancer progression is warranted.
Funder
Canadian Institutes of Health Research
Publisher
Springer Science and Business Media LLC
Subject
Clinical Biochemistry,Biochemistry,Endocrinology, Diabetes and Metabolism
Reference54 articles.
1. Aghili, M., Zare, M., Mousavi, N., Ghalehtaki, R., Sotoudeh, S., Kalaghchi, B., Akrami, S., & Esmati, E. (2019). Efficacy of gabapentin for the prevention of paclitaxel induced peripheral neuropathy: A randomized placebo controlled clinical trial. The Breast Journal, 25(2), 226–231. https://doi.org/10.1111/tbj.13196 2. ALLEN Mouse Brain Atlas, version 2 (2011) (pp. 1–72). (2011). The Allen Institute for Brain Science. https://mouse.brain-map.org/static/atlas 3. Anders, C. K., & Carey, L. A. (2009). Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clinical Breast Cancer, 9(SUPPL.2), S73. https://doi.org/10.3816/CBC.2009.s.008 4. Arai, Y. C. P., Matsubara, T., Shimo, K., Suetomi, K., Nishihara, M., Ushida, T., Kobayashi, K., Suzuki, C., Kinoshita, A., Kondo, M., Matsubara, S., Hayashi, R., Tohyama, Y., Nishida, K., & Arakawa, M. (2010). Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine. Journal of Anesthesia, 24(3), 407–410. https://doi.org/10.1007/s00540-010-0913-6 5. Bowery, N. G., & Smart, T. G. (2006). GABA and glycine as neurotransmitters: A brief history. British Journal of Pharmacology, 147, S109. https://doi.org/10.1038/sj.bjp.0706443
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|